Biotech Developer Divine Skin (DSKX) Announces New Brazilian Division To Exploit Latin American Markets
MIAMI BEACH, Fla., Oct. 4 /PRNewswire/ -- Divine Skin Inc. (OTC Bulletin Board: DSKX) announced the launch of its first Latin American subsidiary, DS Laboratories do Brasil Ltd., with a local office, resident pharmacist, and sales force now in place.
"We are thrilled to be launching in Brazil, the world's second largest cosmetics market after the United States," said Ezio Da Fonseca, president of DS Laboratories do Brasil. "The opportunities here are enormous."
"This is a major milestone in the meteoric growth of Divine Skin worldwide," added Daniel Khesin, founder and chief executive. "We expect Brazilian sales to be visible in 2010 figures and to contribute strongly in 2011 and beyond."
DS Laboratories, Divine Skin's first brand, begins Brazilian marketing operations with several level-1 cosmetics, including its Nia radiant-color shampoo and conditioner and Nirena pH-balanced feminine cleanser.Brazil's regulatory authorities require blind 60-day efficiency tests for level-2 cosmetics such as the company's Oligo.DX advanced cellulite-reducing gel. In studies now concluding, this product has demonstrated an astounding 90-percent success rate. Oligo.DX eliminates the unsightly appearance of dimpled fat, revealing smoother, firmer thighs, buttocks, and hips. The secret of its success is delivering active ingredients deeper, into lower layers of skin where cellulite forms. The formula features micropatch caffeine, proven in studies to penetrate deeper, persist longer, and dissolve lymphatic buildup better than the free form of the same ingredient. Proprietary Nanosome encapsulation assists further with absorption. By the end of October, efficiency tests should wrap up for the company's Revita hair-growth-stimulating shampoo, which delivers ketoconazole, copper peptides, procyanidins, and additional compounds with powerful antioxidant properties, dihydrotestosterone inhibitors, and other hair-growth stimulants. Tests for the rest of DS Laboratories' line are expected to conclude by the end of this year.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts